North America Bladder Cancer Market to Reach $4.3 Billion by 2035 Driven by AI Diagnostics and Advanced Monitoring

North American bladder cancer market was valued at $2.6 billion in 2025 and is projected to reach $4.3 billion by 2035, growing at a CAGR of 5.4% during the forecast period (2026–2035). The North America bladder cancer market is witnessing significant transformation driven by the integration of artificial intelligence (AI) into diagnostic workflows. Increasing disease prevalence, demand for early detection, and pressure to improve clinical efficiency are accelerating the adoption of AI-based diagnostic technologies across the region. AI-powered solutions such as AIxURO enhance urine cytology analysis by improving the detection of atypical and malignant cells, thereby supporting faster and more standardized pathology reporting. Similarly, the TOBY Test, which has received FDA Breakthrough Device Designation, leverages artificial intelligence and metabolomic profiling to enable non-invasive early detection of bladder cancer. These innovations reduce diagnostic turnaround times, enhance accuracy, and minimize unnecessary invasive procedures, thereby increasing patient confidence and healthcare efficiency. Collectively, AI-based bladder cancer diagnostic products are strengthening clinical outcomes while contributing substantially to the expansion and technological advancement of the North American bladder cancer market.

Browse the full report description of “North American Bladder Cancer Market Size, Share & Trends Analysis Report by Cancer Type (Transitional Cell Bladder Cancer/ Urothelial Carcinoma, Squamous Cell Bladder Cancer, Adenocarcinoma, and Other Rare Types) By Diagnosis Method (Cystoscopy, Biopsy, Urinalysis, Urine Cytology, Intravenous Pyelogram (Ivp), and Other) By Therapy (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, and Other), 2026–2035)” at https://www.omrglobal.com/industry-reports/north-american-bladder-cancer-market

AI-Based Bladder Cancer Diagnostic Products and Development Status in North America

Source: Company Website

Bladder cancer represents a significant clinical and economic burden in the United States, particularly among men where it ranks among the most commonly diagnosed cancers. The disease is associated with considerable mortality and a substantial number of new cases each year. Its high long-term recurrence rate, especially in aggressive forms, necessitates continuous monitoring and repeated treatment interventions. As a result, bladder cancer contributes notably to overall national healthcare expenditures and resource utilization.

Bladder Cancer Key Statistics, US (2025)

Source: American Cancer Society

Innovations and Developments in North American Bladder Cancer

The North American bladder cancer market is dominated by major companies including Bristol Myers Squibb Co., Eli Lilly and Company, Incyte Corp, Merck & Co., Inc., and Pfizer Inc., among others. Market participants are advancing diagnostic and treatment capabilities through innovative technologies, AI-driven platforms, and regulatory recognitions.

• In January 2026, CorePlus Servicios Clinicos y Patologicos, LLC announced the implementation of AIxURO, an AI-powered urine cytology platform developed in collaboration with AIxMed, Inc. to enhance bladder cancer detection. The software analyzes whole slide images using AI to identify suspicious cells in accordance with The Paris System for Reporting Urinary Cytology, enabling 100% quality control and reducing diagnostic review time by up to 80%. The initiative aims to improve diagnostic accuracy, accelerate results, and potentially reduce reliance on invasive cystoscopy procedures.

• In June 2025, the US Food and Drug Administration granted Breakthrough Device Designation to TOBY, Inc. for its AI-powered TOBY Test for Bladder Cancer, a non-invasive urine-based diagnostic. The test analyzes volatile organic compounds using gas chromatography–mass spectrometry and proprietary artificial intelligence to generate a real-time cancer risk score, offering a potential alternative to invasive cystoscopy.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Cancer Type
  • By Diagnosis Method
  • By Therapy
• Competitive Landscape - Bristol Myers Squibb Co., Eli Lilly and Company, Incyte Corp, Merck & Co., Inc., and Pfizer Inc., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

North America Bladder Cancer Market Report Segment

By Cancer Type 

• Transitional Cell Bladder Cancer/ Urothelial Carcinoma
• Squamous Cell Bladder Cancer
• Adenocarcinoma
• Others

By Diagnosis Method

• Cystoscopy
• Biopsy
• Urinalysis
• Urine Cytology
• Intravenous Pyelogram (IVP)
• Others

By Therapy

• Surgery
• Chemotherapy
• Immunotherapy
• Radiation Therapy
• Others

North America Bladder Cancer Market Report Segment by Region

• US
• Canada

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/north-american-bladder-cancer-market